http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
CytoSorbents Reports Fourth Quarter and Full Year 2022 Results
-
New European “Guidelines for the Management of Severe Perioperative Bleeding” Consider Hemoadsorption for the First-Time
-
New European “Guidelines for the Management of Severe Perioperative Bleeding” Consider Hemoadsorption for the First-Time
-
CytoSorbents to Present at the Cowen 43rd Annual Health Care Conference
-
CytoSorbents to Report Fiscal 2022 Operating and Financial Results
-
Cytosorbents (CTSO) Issues Stockholder Letter, Reports Preliminary Fourth Quarter and Full Year 2022 Revenue
-
CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2022 Revenue
-
CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial
-
CytoSorbents Appoints Irina B. Kulinets, PhD, as Senior Vice President of Global Regulatory Affairs
-
Cytosorbents (CTSO) Announces $5M in Non-Dilutive Debt Financing
-
CytoSorbents Receives $5M in Non-Dilutive Debt Financing from Bridge Bank and Extends Loan Agreement
-
Cytosorbents (CTSO) Announces DSMB's Recommendation to Continue STAR-T Trial As Planned Without Modifications
-
CytoSorbents Receives Recommendation from Independent Data and Safety Monitoring Board to Continue Pivotal STAR-T Trial As Planned Without Modifications
-
CytoSorbents Announces Pivotal STAR-T Trial Reaches First Milestone With 40 Patients Enrolled
-
CytoSorbents Reports Third Quarter 2022 Financial and Operational Results
-
Cytosorbents (CTSO) Announces CytoSorb and ECMO Achieves High Survival in 100 Critically Ill COVID-19 Patients
-
'Enhanced Lung Rest' with CytoSorb and ECMO Achieves High Survival in 100 Critically Ill COVID-19 Patients with Refractory Lung Failure from Five Major U.S. Hospitals
-
Cytosorbents (CTSO) Announces National Institutes of Health Grants Phase I SBIR Award to it to Test Novel Polymers for Cytokine and Endotoxin Removal from Septic Porcine Plasma
-
National Institutes of Health Grants Phase I SBIR Award to CytoSorbents to Test Novel Polymers for Cytokine and Endotoxin Removal from Septic Porcine Plasma
-
CytoSorbents to Report Third Quarter 2022 Operating and Financial Results
-
Cytosorbents (CTSO) Reports New Cardiac Surgery Data with CytoSorb
-
CytoSorbents Reports New Cardiac Surgery Data with CytoSorb at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting
-
Cytosorbents (CTSO) Announces Pending Retirement of Chief Financial Officer Kathleen P. Bloch
-
CytoSorbents Announces Pending Retirement of Chief Financial Officer Kathleen P. Bloch
-
Cytosorbents (CTSO) Awarded $4.3M Contract by the U.S. DoD to Develop HemoDefend-BGA
-
CytoSorbents Awarded an Approximately $4.3M Contract by the U.S. Department of Defense to Develop HemoDefend-BGA™ for Freeze-Dried Universal Plasma
-
CytoSorbents to Present at the Dawson James Securities 2022 Small Cap Growth Conference
-
Cytosorbents (CTSO) Achieves ISO 13485 Certification of Princeton Manufacturing Facility in New Jersey
-
CytoSorbents Achieves ISO 13485 Certification of Princeton Manufacturing Facility in New Jersey
-
Cytosorbents (CTSO) Announces U.S. Department of Defense Awards it an Approximately $2.0M Contract to Support HemoDefend-BGA™ Development for Life-saving Universal Plasma
-
The U.S. Department of Defense Awards CytoSorbents an Approximately $2.0M Contract to Support HemoDefend-BGA™ Development for Life-saving Universal Plasma
-
CytoSorbents to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
Cytosorbents' (CTSO) CytoSorb Granted National Reimbursement in Turkey
-
Turkish Ministry of Health Grants National Reimbursement to CytoSorb®
-
Cytosorbents (CTSO) Announces Israeli Approval of National Coverage for CytoSorb
-
Israeli Ministry of Health Approves National Coverage for CytoSorb®
-
CytoSorb® Becomes a Featured Blood Purification Therapy on Fresenius Medical Care Critical Care Platforms
-
CytoSorbents Reports Second Quarter 2022 Financial and Operational Results
-
CytoSorbents to Report Second Quarter 2022 Operating and Financial Results
-
The 2022 CytoSorb World Users' Meeting Highlights the Broad Market Potential of CytoSorb as an Interdisciplinary Therapeutic Approach
-
Leading Critical Care and Cardiac Surgery Specialists from 40 Countries Meet to Discuss CytoSorb and the New Dimension in Blood Purification
-
CytoSorbents to Hold 2022 Annual Meeting of Stockholders Virtually
-
CytoSorbents Partners with Nikkiso to Distribute the PureADJUST Hemoperfusion Blood Pump and Supplies in 14 Countries
-
CytoSorbents to Present at Two Upcoming Investor Conferences
-
CytoSorbents Reports First Quarter 2022 Results and Revises 2022 Outlook
-
Cytosorbents (CTSO) Awarded Preferred Supplier Agreement with Asklepios
-
CytoSorbents Awarded Preferred Supplier Agreement with Asklepios, One of the Largest Private Hospital Operators in Germany
-
First Patient Enrolled in U.S. STAR-D Pivotal Trial Evaluating the DrugSorb™-ATR Antithrombotic Removal System to Remove Apixaban and Rivaroxaban During Cardiothoracic Surgery
-
CytoSorbents Highlights the Strategy of "Enhanced Lung Rest" Using CytoSorb with ECMO to Help Treat Lung Failure at the 10th EuroELSO Congress
-
CytoSorbents to Report First Quarter 2022 Operating and Financial Results

